Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
Holding MIRM?
Track your performance easily
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.14 - $45.23
Previous Close$38.93
Volume639.41K
Average Volume (3M)594.33K
Market Cap
$1.86B
Enterprise Value$1.90B
Total Cash (Recent Filing)$278.37M
Total Debt (Recent Filing)$316.56M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 06, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding47,707,204
10 Day Avg. Volume475,728
30 Day Avg. Volume594,327
Standard Deviation0.35
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)8.12
Price to Sales (P/S)7.03
Price to Cash Flow (P/CF)-122.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.17
Enterprise Value/Gross Profit13.60
Enterprise Value/Ebitda-45.91
Forecast
1Y Price Target
$60.11Price Target Upside54.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Mirum Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMIRM announced positive data from the interim analyses of its Phase 2b trials of volixibat in PBC and PSC, showing statistically significant improvements in pruritus vs. placebo.
Drug ApprovalThe FDA has approved a label expansion of LIVMARLI for the treatment of cholestatic pruritus in PFIC patients, now including those aged 12 months and older.
Revenue GrowthMirum Pharmaceuticals remains on track to hit its revenue guidance of $310-$320M with several recent wins across its pipeline.
Bears Say
Product SafetyThe new label includes a warning to monitor for propylene glycol toxicity in younger patients.
Regulatory ApprovalsFailure to secure additional regulatory approvals for LIVMARLI.
Sales GrowthSales growth of LIVMARLI for ALGS and PFIC significantly below expectations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $45.23 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2024 which is in 42 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Aug 07, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.472 by -$0.048.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.43.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 47,707,203 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.472. Following the earnings report the stock price went up 2.336%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Mirum Pharmaceuticals Inc’s shares valued at 7M.
---
Mirum Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.11 (54.21% Upside)
$60.11 (54.21% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 96.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.72%
12-Months-Change
Fundamentals
Return on Equity
-69.35%
Trailing 12-Months
Asset Growth
48.96%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Earnings Call
Q2 2024
0:00 / 0:00
---
MIRM Stock 12 Month Forecast
Average Price Target
$60.11
▲(54.21% Upside)
Technical Analysis
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
31/34 ratings generated profit
1 Year Average Return
+33.62%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 91.18% of your transactions generating a profit, with an average return of +33.62% per trade.
---